contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


episurf-interim-report-1-january-30-june-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Episurf Medical är verksamt inom medicinteknikbranschen och fokuserar på utveckling och tillverkning av individuellt anpassade implantat för ledreparation. Bolagets produkter riktar sig till kirurger och sjukvårdsinstitutioner. Verksamheten är global med en huvudsaklig närvaro i Europa, Nordamerika och Asien. Episurf Medical grundades 2008 och har sitt huvudkontor i Stockholm.

Episurf Medical

· Improved results of SEK 7.0m adjusted for re-structuring provision of SEK 3.1m, with additional cost savings identified · More than 100% growth in the U.S. customer base and continued expansion...

· Improved results of SEK 7.0m adjusted for re-structuring provision of SEK 3.1m, with additional cost savings identified · More than 100% growth in the U.S. customer base and continued expansion of the U.S. distributor network, with a 46% increase in order intake during the first half of the year in the U.S. · Ongoing establishment of European distribution operations through collaboration with Joint Operations"During the second quarter, we made significant changes to our operations and announced further measures toward the end of the period. We now have a strong sales partner for our key European markets through Joint Operations, as well as solid representation in several other European countries. Our presence in the U.S. market is growing. During the quarter, we recorded a restructuring provision of SEK 3.1m. We have communicated a target of achieving additional annual cost savings of SEK 20.0m. Adjusted EBIT for Q2 2025 amounted to SEK -14.4m, representing an improvement of 33%, or SEK 7.0m, compared to the same quarter last year. With further savings ahead, we aim to significantly reduce our cost base, which - together with expected sales growth - gives us a solid foundation to continue improving our results and financial position", says Pål Ryfors, CEO Episurf Medical.Second quarter 2025 compared to 2024, Group » Gross order intake amounted to SEK 3.5m (3.5) » Group net sales amounted to SEK 2.9m (3.2) » Order book amounted to SEK 2.2m (2.0) » Loss for the period amounted to SEK -17.7m (-21.4), including SEK 3.1m re-structuring provision » Earnings per share amounted to SEK -0.03 (-0.07)First six months 2025 compared to 2024, Group » Gross order intake amounted to SEK 7.2m (6.2) » Group net sales amounted to SEK 6.8m (6.2) » Loss for the period amounted to SEK -34.3m (-42.0) » Earnings per share amounted to SEK -0.05 (-0.13)Significant events during the sec ond quarter 2025 » Episurf Medical has made progress in the FDA process for the Episealer® MTP implant, but certain validation activities remain, and the company is now following the FDA's guidance with a concrete plan to complete the processSignificant events during pr evious quarters 2025 » Episurf Medical announced that theresponse to the US FDA has been filed and addresses a request for additional information on the company's Episealer® MTP implant » Episurf Medical entered into a distribution agreement for several European countries with Joint Operations Ltd » Episurf Medical announced the outcome of the exercise of warrants of series TO13B » Episurf Medical announced that CFO Veronica Wallin will leave for a new postionSignificant events after the quarter » Episurf Medical announced re-structuring initiatives and increased focus towards the US market » Episurf Medical announced a rights issue of units of up to approximately SEK 29.4m<div></div>